ImaginAb touts research on T-cell PET imaging agent

2018 11 06 23 34 9504 Pet Scan Patient 400

Imaging agent developer ImaginAb said data from the first-in-human imaging study of its CD8 T-cell PET agent for use in detecting solid malignancies were published online October 4 in the Journal of Nuclear Medicine.

The research showed that ImaginAb's CD8 zirconium-89 (Zr-89) IAB22M2C agent was well tolerated with no immediate or delayed side effects, according to the firm. The biodistribution of the agent also suggested that CD8+ T cell-rich tissues were successfully targeted. The observed targeting of tumor lesions indicates the agent may be helpful for assessing the accumulation of CD8+ T cells within tumors, the company said.

The tracer is currently in phase II clinical trials.

Page 1 of 435
Next Page